Medically reviewed by Michael MacIntyre, MDSchizophrenia medication falls under two main categories: older, first-generation, ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

Depression and anxiety are the most common psychiatric disorders in the world. Around 300 million people suffer from ...

In a review study, researchers reported that omega-3 supplements may lessen the severity of schizophrenia symptoms in teens and young adults, especially those with low levels of omega-3s.

Two specific types of antidepressants – selective serotonin reuptake inhibitors (SSRIs) and tricyclics (TCAs) – may make ...

Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal.

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

A Brandon judge is considering going above the Crown’s suggested sentence for a man who pleaded guilty to masturbating in ...

Here’s how it treats schizophrenia and bipolar depression. Skip to main content . Home ; Conditions . ... In both studies, people took either Caplyta or a placebo (a pill with no medicine).